These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 25724929)

  • 1. Delivering nanomedicines to patients: a practical guide.
    Eaton MA; Levy L; Fontaine OM
    Nanomedicine; 2015 May; 11(4):983-92. PubMed ID: 25724929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improving the translation in Europe of nanomedicines (a.k.a. drug delivery) from academia to industry.
    Eaton MA
    J Control Release; 2012 Dec; 164(3):370-1. PubMed ID: 22721816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Challenges of clinical translation in nanomedicine: A qualitative study.
    Satalkar P; Elger BS; Hunziker P; Shaw D
    Nanomedicine; 2016 May; 12(4):893-900. PubMed ID: 26772431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The nanomedicines alliance: an industry perspective on nanomedicines.
    Malinoski FJ
    Nanomedicine; 2014 Nov; 10(8):1819-20. PubMed ID: 25038497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanomedical engineering: shaping future nanomedicines.
    Luo D; Carter KA; Lovell JF
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2015; 7(2):169-88. PubMed ID: 25377691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanomedicine applied to translational oncology: A future perspective on cancer treatment.
    Bregoli L; Movia D; Gavigan-Imedio JD; Lysaght J; Reynolds J; Prina-Mello A
    Nanomedicine; 2016 Jan; 12(1):81-103. PubMed ID: 26370707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanomedicines: From Bench to Bedside and Beyond.
    Havel H; Finch G; Strode P; Wolfgang M; Zale S; Bobe I; Youssoufian H; Peterson M; Liu M
    AAPS J; 2016 Nov; 18(6):1373-1378. PubMed ID: 27480318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Challenges in nanomedicine clinical translation.
    Metselaar JM; Lammers T
    Drug Deliv Transl Res; 2020 Jun; 10(3):721-725. PubMed ID: 32166632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High drug-loading nanomedicines: progress, current status, and prospects.
    Shen S; Wu Y; Liu Y; Wu D
    Int J Nanomedicine; 2017; 12():4085-4109. PubMed ID: 28615938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current hurdles to the translation of nanomedicines from bench to the clinic.
    Đorđević S; Gonzalez MM; Conejos-Sánchez I; Carreira B; Pozzi S; Acúrcio RC; Satchi-Fainaro R; Florindo HF; Vicent MJ
    Drug Deliv Transl Res; 2022 Mar; 12(3):500-525. PubMed ID: 34302274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical translation of nanomedicines: Challenges, opportunities, and keys.
    Younis MA; Tawfeek HM; Abdellatif AAH; Abdel-Aleem JA; Harashima H
    Adv Drug Deliv Rev; 2022 Feb; 181():114083. PubMed ID: 34929251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanomedicine drug development: a scientific symposium entitled "Charting a roadmap to commercialization".
    Finch G; Havel H; Analoui M; Barton RW; Diwan AR; Hennessy M; Reddy V; Sadrieh N; Tamarkin L; Wolfgang M; Yerxa B; Zolnik B; Liu M
    AAPS J; 2014 Jul; 16(4):698-704. PubMed ID: 24821054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanomedicines and nanodiagnostics come of age.
    Uchegbu IF; Siew A
    J Pharm Sci; 2013 Feb; 102(2):305-10. PubMed ID: 23175462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting Brain Tumors with Nanomedicines: Overcoming Blood Brain Barrier Challenges.
    Khaitan D; Reddy PL; Ningaraj N
    Curr Clin Pharmacol; 2018; 13(2):110-119. PubMed ID: 29651960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combining Nanomedicine and Immunotherapy.
    Shi Y; Lammers T
    Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Critical quality attributes in the development of therapeutic nanomedicines toward clinical translation.
    Taha MS; Padmakumar S; Singh A; Amiji MM
    Drug Deliv Transl Res; 2020 Jun; 10(3):766-790. PubMed ID: 32170656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine?
    Danhier F
    J Control Release; 2016 Dec; 244(Pt A):108-121. PubMed ID: 27871992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer Nanomedicines.
    Tang J; Pérez-Medina C; Zhao Y; Sadique A; Mulder WJ; Reiner T
    J Vis Exp; 2017 Mar; (121):. PubMed ID: 28287606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survey of Clinical Translation of Cancer Nanomedicines-Lessons Learned from Successes and Failures.
    He H; Liu L; Morin EE; Liu M; Schwendeman A
    Acc Chem Res; 2019 Sep; 52(9):2445-2461. PubMed ID: 31424909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging nanomedicine applications and manufacturing: progress and challenges.
    Sartain F; Greco F; Hill K; Rannard S; Owen A
    Nanomedicine (Lond); 2016 Mar; 11(6):577-80. PubMed ID: 26911307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.